PsyBio Therapeutics Files Patent Application with USPTO for Production Methods of Methylated Trypatamines and Associated… Aug 16, 2021
PsyBio Therapeutics Adds NMDA Receptor Antagonists and Associated Analogues into its Intellectual Property Portfolio Aug 4, 2021
PsyBio Therapeutics Files Patent for Psilocybin and Norbaeocystin Mental Health Treatments Jul 16, 2021
PsyBio Therapeutics Augments Intellectual Property Portfolio with Filing of Next Novel Psychedelic Compositions and… Jul 13, 2021
The Latest On Psybio Therapeutics: CEO Evan Levine Comments On Maxim Group Buy Rating, European Research, And More Jul 6, 2021
PsyBio Therapeutics Initiates European Manufacturing of Proprietary Biosynthetic Psychedelic Compounds including… Jun 22, 2021
PsyBio Therapeutics Reports First Quarter 2021 Financial Results, Provides Shareholder Update and Announces Intention to… Jun 1, 2021
Psybio Therapeutics CEO Evan Levine: “Our Method Synthesizes Psilocybin Cheaper, Faster, And Greener” Than The Others May 13, 2021
